China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo ...

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Heterozygous familial hypercholesterolemia was associated with increased type 2 diabetes risk, especially among those with obesity and statin use.

AL002 is a monoclonal antibody that Alector was developing to slow down Alzheimer’s progression. Image credit: Black Salmon / Shutterstock. Alector’s internal pipeline suffered a blow as the Phase II ...

Three unrelated children were found to have a de novo deletion in the long non-coding RNA (lncRNA) CHASERR, which is adjacent ...

The trial of the combination of obicetrapib and ezetimibe is designed to work for patients whom existing cholesterol ...

Zinc supplementation was started. Genetic testing done simultaneously showed compound heterozygous mutations in SLC39A4 in ...

NewAmsterdam Pharma’s lead cardio program obicetrapib passed another Phase 3 trial, demonstrating its ability to lower “bad ...

Praluent is a prescription drug used for certain conditions, including high cholesterol. Find out about possible interactions ...

Dutch biotech NewAmsterdam Pharma (NASDAQ:NAMS) announced Wednesday that its oral anti-cholesterol therapy containing ...

During the Phase III BROOKLYN trial, patients were randomly assigned in a 2:1 ratio to receive either obicetrapib 10mg or a ...

The data showed that the obicetrapib and ezetimibe fixed-dose combination observed to lower LDL-C by approximately 50% at day 84, compared to placebo, with over 70% of patients achieving LDL-C levels ...